Comparative Pharmacology
Head-to-head clinical analysis: NORTREL 0 5 35 21 versus OGESTREL 0 5 50 21.
Peer-Reviewed Evidence
Head-to-head clinical analysis: NORTREL 0 5 35 21 versus OGESTREL 0 5 50 21.
NORTREL 0.5/35-21 vs OGESTREL 0.5/50-21
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Combination hormonal contraceptive containing norethindrone (a progestin) and ethinyl estradiol (an estrogen). Norethindrone inhibits ovulation by suppressing gonadotropin release (LH and FSH) and alters cervical mucus and endometrial receptivity. Ethinyl estradiol provides negative feedback on the hypothalamic-pituitary-ovarian axis, further suppressing ovulation.
Combination of norgestrel and ethinyl estradiol suppresses gonadotropin release, inhibiting ovulation; alters cervical mucus and endometrial lining.
1 tablet orally once daily for 21 days, followed by 7 days off. Each tablet contains 0.5 mg norethindrone and 35 mcg ethinyl estradiol.
One tablet (norgestrel 0.5 mg / ethinyl estradiol 0.05 mg) orally once daily for 21 days, followed by 7 placebo days.
None Documented
None Documented
Norethindrone: terminal half-life approximately 7-8 hours. Ethinyl estradiol: terminal half-life approximately 13-27 hours, mean about 17 hours. Ethinyl estradiol exhibits a longer half-life due to enterohepatic recirculation and extensive tissue distribution.
Norgestrel: 24-32 hours; Ethinyl estradiol: 7-12 hours. Clinical context: Steady state achieved after 5-7 days.
Norethindrone is primarily excreted renally (approximately 60-80% as metabolites) and approximately 20-40% fecally. Ethinyl estradiol is excreted renally (about 40%) and fecally (about 60%) as glucuronide and sulfate conjugates.
Renal: ~50% (metabolites); Fecal/Biliary: ~50% (metabolites); <1% unchanged in urine.
Category C
Category C
Oral Contraceptive
Oral Contraceptive